Companion Animal Postoperative Pain Management Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal (Dogs, Cats, Horses, Others), By Product (NSAIDs, Anesthetics, Opioids, Others), By Route of Administration (Oral, Injectable), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 214.56 Million
CAGR (2026-2031)	8.22%
Fastest Growing Segment	NSAIDs
Largest Market	North America
Market Size (2031)	USD 344.66 Million

Market Overview

The Global Companion Animal Postoperative Pain Management Therapeutics Market will grow from USD 214.56 Million in 2025 to USD 344.66 Million by 2031 at a 8.22% CAGR. Companion animal postoperative pain management therapeutics encompass pharmaceutical agents, such as non-steroidal anti-inflammatory drugs and opioids, utilized to mitigate acute pain in pets following surgical procedures. The market is fundamentally driven by the increasing volume of orthopedic and dental surgeries performed in veterinary clinics, coupled with the elevation of clinical standards regarding animal welfare. Additionally, the expansion of veterinary infrastructure and the availability of novel drug delivery systems further support the demand for effective pain relief solutions.

Market growth is reinforced by substantial financial commitment from owners regarding animal health. According to the American Pet Products Association, in 2024, United States expenditure on veterinary care and product sales reached $39.8 billion. Despite this robust spending, the high cost associated with advanced surgical interventions and subsequent pain management protocols presents a significant challenge, as it may restrict access to optimal care for economically constrained pet owners, thereby impeding broader market expansion.

Key Market Drivers

Rising rates of companion animal ownership and adoption act as a primary catalyst for the Global Companion Animal Postoperative Pain Management Therapeutics Market. As the pet population expands, the absolute number of animals requiring veterinary attention, including surgical interventions for orthopedic conditions, soft tissue injuries, and dental diseases, naturally increases. This surge creates a direct pipeline for postoperative pain management therapeutics, as an increased patient base necessitates a higher volume of analgesic prescriptions. Furthermore, the deepening human-animal bond compels owners to seek advanced medical care, ensuring their pets receive the same standard of pain relief as humans. According to UK Pet Food, March 2024, in the 'Pet Data Report 2024', the pet population in the United Kingdom reached 36 million, with 60% of households owning a companion animal. This substantial ownership base significantly expands the addressable market for effective postoperative therapeutic solutions.

Advancements in analgesic drug development and delivery systems serve as the second critical driver, fundamentally altering clinical treatment protocols. The market is shifting from traditional short-acting opioids and non-steroidal anti-inflammatory drugs toward long-acting, targeted therapies such as monoclonal antibodies, which offer improved safety profiles and compliance for chronic and postoperative pain. These innovations encourage veterinarians to prescribe pain management more frequently and for longer durations. This trend is evident in the performance of market leaders; according to Zoetis, November 2024, in the 'Third Quarter 2024 Financial Results', the company's monoclonal antibody portfolio for osteoarthritis pain, including Librela and Solensia, achieved 97% operational revenue growth globally. The robust financial health of the sector supports continued innovation; according to Elanco Animal Health, February 2024, the company reported full-year 2023 revenue of $4.417 billion, highlighting the significant investment capacity available for developing next-generation veterinary therapeutics.

Download Free Sample Report

Key Market Challenges

The high cost associated with advanced surgical interventions and subsequent pain management protocols stands as a significant barrier impeding the growth of the Global Companion Animal Postoperative Pain Management Therapeutics Market. When veterinary care becomes financially prohibitive, economically constrained pet owners are often forced to decline necessary orthopedic or dental surgeries for their companions. Since the demand for postoperative pain therapeutics is inextricably linked to the volume of surgical procedures performed, any reduction in surgical case-loads directly diminishes the total addressable market for these pharmaceutical agents.

This financial pressure forces owners to delay or completely potential veterinary treatments, effectively contracting the customer base for prescription pain relief solutions. Evidence of this trend is visible in recent industry data which highlights a decline in veterinary utilization. According to the American Veterinary Medical Association, data collected between August 2023 and August 2024 revealed a 2.3% decrease in patient visits across veterinary practices in the United States. This decline in engagement suggests that rising costs are compelling owners to forego professional care, thereby reducing the opportunities for veterinarians to prescribe and administer postoperative analgesics.

Key Market Trends

The Shift Toward Opioid-Sparing and Non-Opioid Therapeutics is rapidly redefining clinical practices within the Global Companion Animal Postoperative Pain Management Therapeutics Market. This trend is primarily propelled by increasing regulatory scrutiny on opioid prescriptions and persistent supply chain instabilities that jeopardize the availability of controlled substances for veterinary use. Clinicians are consequently pivoting toward multimodal protocols that prioritize non-steroidal anti-inflammatory drugs (NSAIDs), local anesthetics, and alpha-2 agonists to minimize reliance on systemic opioids while ensuring effective analgesia. The urgency of this transition is underscored by supply constraints; according to the American Society of Health-System Pharmacists (ASHP), December 2024, in the 'Drug Shortages Statistics', there were 214 active drug shortages in the United States, with significant disruptions reported in the supply of opioid analgesics essential for acute pain control, compelling practitioners to adopt alternative therapeutic strategies.

Simultaneously, the Development of Liposome-Encapsulated Drug Technologies is emerging as a transformative approach for extending the duration of postoperative pain relief. These advanced formulations, such as liposomal bupivacaine, allow for the single administration of a local anesthetic that releases the active pharmaceutical ingredient over several days, thereby covering the critical 72-hour post-surgical window without the need for catheters or repeated injections. This technology addresses compliance challenges and reduces the stress associated with frequent medication administration in recovering pets. The commercial success of companies investing in these specialized delivery platforms validates the market's trajectory; according to Elanco Animal Health, November 2024, in the 'Third Quarter 2024 Financial Results', the company reported Pet Health revenue of $486 million, reinforcing the robust financial viability of its specialized surgical and pain management portfolio which includes advanced long-acting therapeutics.

Segmental Insights

The Non-steroidal anti-inflammatory drugs segment currently represents the fastest-growing category within the global companion animal postoperative pain management therapeutics market. This rapid expansion is primarily driven by the cost-effectiveness and broad availability of these medications relative to other analgesic classes. Market growth is further accelerated by the frequent approval of safer, species-specific formulations by regulatory authorities such as the U.S. Food and Drug Administration. Additionally, the development of convenient oral and injectable dosage forms significantly improves treatment compliance among pet owners, establishing NSAIDs as the preferred option for controlling inflammation and acute pain following surgical procedures.

Regional Insights

North America holds the leading position in the global companion animal postoperative pain management therapeutics market, driven by a well-established veterinary healthcare infrastructure and high rates of pet ownership. The region exhibits significant expenditure on animal health services, supported by a cultural emphasis on animal welfare that encourages surgical interventions and necessary pain management. Additionally, the market is strengthened by the presence of key industry players and favorable regulatory frameworks from agencies like the U.S. Food and Drug Administration, which facilitate the timely approval and availability of therapeutic options.

Recent Developments

• In October 2025, Zoetis Inc. announced that it had received approval from Health Canada for Lenivia (izenivetmab injection), a novel monoclonal antibody therapy designed for the alleviation of pain in dogs. This long-acting therapeutic targets nerve growth factor (NGF) to provide sustained pain relief for up to three months with a single injection. While primarily indicated for osteoarthritis, the launch of such advanced biologic therapies by a market leader signifies a major technological shift in the broader companion animal pain management landscape, influencing how veterinary professionals approach long-term and potential perioperative pain strategies with innovative, non-opioid solutions.
• In August 2025, Cronus Pharma Specialities India Private Ltd. secured FDA approval for Meloxisol (meloxicam oral suspension), expanding the available therapeutic options for managing pain in companion animals. Meloxicam is a widely utilized non-steroidal anti-inflammatory drug in veterinary medicine, frequently prescribed for both the control of pain and inflammation associated with osteoarthritis and for off-label or indicated use in postoperative pain management protocols. The approval of this generic formulation provided a new, bioequivalent alternative to existing meloxicam products, reinforcing the supply chain for critical analgesics used in veterinary surgical recovery and chronic pain care.
• In September 2024, Felix Pharmaceuticals Pvt. Ltd. received approval from the U.S. Food and Drug Administration (FDA) for its generic Carprofen Soft Chewable Tablets, a non-steroidal anti-inflammatory drug (NSAID) indicated for the relief of pain and inflammation. The approval explicitly covered the use of the medication for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs, directly addressing the core needs of the postoperative pain management therapeutics market. This product launch introduced a cost-effective therapeutic option for veterinary professionals and pet owners, ensuring wider access to essential postoperative analgesia for canine patients.
• In July 2024, Dechra Pharmaceuticals Limited announced the acquisition of Invetx, a Boston-based biotechnology company specializing in protein-based therapeutics for companion animals. This strategic move was designed to bolster Dechra’s innovation pipeline within the companion animal healthcare sector, particularly in the domain of monoclonal antibodies (mAbs) for treating chronic conditions. The acquisition provided Dechra with access to a proprietary platform for extending the half-life of therapeutics, thereby enhancing its capabilities in developing long-acting pain management solutions. This collaboration significantly strengthens Dechra's position in the broader pain management therapeutics market, complementing its existing portfolio of postoperative and acute pain treatments.

Key Market Players

• Zoetis Inc.
• Merck & Co., Inc.
• Elanco Animal Health Inc.
• Ceva Santé Animale S.A.
• Boehringer Ingelheim International GmbH
• Norbrook Laboratories
• Dechra Pharmaceuticals PLC
• Chanelle Pharma
• Bimeda Holdings Limited
• VETOQUINOL S.A.

By Animal	By Product	By Route of Administration	By Region
Dogs Cats Horses Others	NSAIDs Anesthetics Opioids Others	Oral Injectable	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Companion Animal Postoperative Pain Management Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Companion Animal Postoperative Pain Management Therapeutics Market , By Animal:

• Dogs
• Cats
• Horses
• Others

• Companion Animal Postoperative Pain Management Therapeutics Market , By Product:

• NSAIDs
• Anesthetics
• Opioids
• Others

• Companion Animal Postoperative Pain Management Therapeutics Market , By Route of Administration:

• Oral
• Injectable

• Companion Animal Postoperative Pain Management Therapeutics Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE